Immunotherapy Archives

July 13, 2022

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

This should not be part of anyone’s game plan. Still, it was nice to read that for at least this one 67-year-old asymptomatic CLL patient, a case of COVID-19 associated with low blood counts and a broad spectrum of treatments resulted in his CLL becoming undetectable in his bone

March 21, 2022

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

Immunotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL / SLL holds the promise of harnessing the body’s immune system to recognize and eliminate cancer.

December 4, 2020

ASH 2019: Dr. Adrian Wiestner on Bispecific Antibodies for Treating CLL (Chronic Lymphocytic Leukemia)

Also during ASH 2019, Dr. Koffman interviewed Dr. Adrian Wiestner, who discussed bi-specific antibodies to improve the immune system in CLL patients. There is reason to believe that when used in combination with a BTK inhibitor such as ibrutinib, they would have increased effectiveness, as ibrutinib improves T cell

December 4, 2020

ASH 2019: Dr. Krish Patel on Harnessing the Immune System in Chronic Lymphocytic Leukemia (CLL) and Other Lymphomas Using Bispecific Antibodies

Dr. Brian Koffman interviewed Dr. Krish Patel at ASH 2019, about how our native immune system is excellent at controlling cancer when it is working normally. In CLL, the immune system has become dysregulated and does a poor job controlling cancer. Could modifying the immune system with off-the-shelf bi-specific

September 10, 2020

ASH 2019: Dr. Neil Kay on Ibrutinib and Rituximab for Chronic Lymphocytic Leukemia (CLL)

The ECOG (E1912) Phase III, randomized, open label, clinical trial, comparing the efficacy of combination ibrutinib and rituximab with standard chemo-immunotherapy (FCR in patients 70 years of age or younger with previously untreated CLL) was a huge game-changer for CLL patients. We are happy to share with you Dr.

June 24, 2020

Bispecific Antibodies: what are they and are they the future of treatment for CLL (chronic lymphocytic leukemia)?

June 24, 2020

ASH 2019: Dr. Schuster on Mosunetuzumab, a Bispecific Antibody in Poor Prognosis Non-Hodgkin Lymphoma Patients

August 11, 2019

Biosimilars

“Biosimilars” are equivalent versions of monoclonal antibodies that have previously been FDA approved to treat various diseases. Because antibodies are more complicated than simple drugs like acetaminophen and aspirin, etc., these drugs are not chemically identical to the original drug. The main advantage of biosimilars is the reduction in

August 6, 2019

Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right?

When CNN has a headline that Chemo-free drug combo shows ‘dramatic’ improvement against common leukemia in adults and reports on a medical journal article on a rare disease such as CLL that’s big news, isn’t it? When New England Journal of Medicine (NEJM), arguably the most prestigious medical journal

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Immunotherapy

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

ASH 2019: Dr. Adrian Wiestner on Bispecific Antibodies for Treating CLL (Chronic Lymphocytic Leukemia)

ASH 2019: Dr. Krish Patel on Harnessing the Immune System in Chronic Lymphocytic Leukemia (CLL) and Other Lymphomas Using Bispecific Antibodies

ASH 2019: Dr. Neil Kay on Ibrutinib and Rituximab for Chronic Lymphocytic Leukemia (CLL)

Bispecific Antibodies: what are they and are they the future of treatment for CLL (chronic lymphocytic leukemia)?

ASH 2019: Dr. Schuster on Mosunetuzumab, a Bispecific Antibody in Poor Prognosis Non-Hodgkin Lymphoma Patients

Biosimilars

Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT